Unihealth Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 02-07-2024
- Paid Up Capital ₹ 0.11 M
as on 02-07-2024
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.25 M
as on 02-07-2024
- Revenue -61.21%
(FY 2023)
- Profit 67.08%
(FY 2023)
- Ebitda 45.60%
(FY 2023)
- Net Worth 101.73%
(FY 2023)
- Total Assets -41.38%
(FY 2023)
About Unihealth Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹3.25 M.
Anurag Shah, Akshay Parmar, and Prafulla Parmar serve as directors at the Company.
- CIN/LLPIN
U52100MH2011PTC223934
- Company No.
223934
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Nov 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Unihealth Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anurag Shah  | Director | 15-Nov-2011 | Current |
| Akshay Parmar | Director | 15-Nov-2011 | Current |
| Prafulla Parmar | Director | 08-Aug-2023 | Current |
Financial Performance of Unihealth Pharmaceuticals.
Unihealth Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 61.21% decrease. The company also saw a substantial improvement in profitability, with a 67.08% increase in profit. The company's net worth Soared by an impressive increase of 101.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unihealth Pharmaceuticals?
In 2023, Unihealth Pharmaceuticals had a promoter holding of 99.99% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aarzeal Technologies Private LimitedActive 7 years 10 monthsAnurag Shah and Akshay Parmar are mutual person
Unihealth Consultancy LimitedActive 14 years 9 monthsAnurag Shah and Akshay Parmar are mutual person
Aryavarta Trading Private LimitedActive 13 years 11 monthsAnurag Shah and Akshay Parmar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Aug 2023 | ₹3.25 M | Open |
How Many Employees Work at Unihealth Pharmaceuticals?
Unlock and access historical data on people associated with Unihealth Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unihealth Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unihealth Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
